aidsmap news story
Eight-weekly injectable treatment with cabotegravir and rilpivirine proved superior to oral daily treatment with dolutegravir and two other drugs in maintaining viral suppression among adolescents in Africa, researchers from the LATA study reported at AIDS 2026.
Adolescents often experience difficulties in adhering to daily oral antiretroviral treatment and have poorer treatment outcomes than adults. Several studies have shown that adolescents who switch from oral to injectable antiretroviral treatment prefer injections and do not experience virologic rebound.
The LATA trial is the first randomised comparison of injectable treatment and oral antiretroviral treatment in adolescents. The study compared standard oral antiretroviral treatment with dolutegravir, tenofovir disoproxil and lamivudine to injections of cabotegravir and rilpivirine every eight weeks.
Read the full news story here.
View all aidsmap reports from AIDS 2026
Source : aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.